Recent Updates
Recently added Catalysts

AGN-190168 Formulation 1

Phase 1

Acne Vulgaris | Small molecule | Dermatology |AbbVie Inc.|Last Updated: Apr 30, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment78
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02218034Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne VulgarisPHASE1 COMPLETED 78Aug 1, 2014Mar 1, 2015Apr 30, 20151 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Maximum Plasma Level (Cmax) of AGN-190168
Day 29
Maximum Plasma Level (Cmax) of AGN-190168 Metabolite
Day 29
Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale
Day 29
Local Dermal Tolerability as Assessed by the Investigator Using a 4-Point Scale
Day 29
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeBASIC_SCIENCE
Treatment Arms
ArmTypeDescription
AGN-190168 Formulation 1EXPERIMENTALAGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
AGN-190168 Formulation 2EXPERIMENTALAGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
TAZORAC® Gel 0.1%ACTIVE_COMPARATORTAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
TAZORAC® Cream 0.1%ACTIVE_COMPARATORTAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Interventions
NameTypeDescription
AGN-190168 Formulation 1DRUGAGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
AGN-190168 Formulation 2DRUGAGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
tazarotene gel 0.1%DRUGTazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
tazarotene cream 0.1%DRUGTazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Diagnosis of acne vulgaris on the face * No tobacco use for the past 30 days, and willing to refrain from nicotine use during the study * Willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet light (eg, sunlight, tanning beds) and extremes in weat...

Countries:United States
Unlock Eligibility Criteria